Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS25DL)

• Drug Name: GS-1423 Drug Info
• Synonyms: AGEN 1423

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMS25DL

Molecule-Related Drug Atlas

Drug(s) Targeting Transforming growth factor beta (TGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[3]
Bintrafusp alfa	DMB9LRJ	Non-small-cell lung cancer	2C25	Phase 2	[4]
NIS793	DM8LBYT	Pancreatic ductal carcinoma	2C10.0	Phase 2	[3]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[5]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[6]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[8]
AVID200	DMZ39T6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
RG6440	DMVQXFH	Aggressive cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Ecto-5'-nucleotidase (CD73)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TJ004309	DMFB54Y	Ovarian cancer	2C73	Phase 2	[11]
Oleclumab	DMLVNWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
AB680	DMGONUE	Pancreatic cancer	2C10	Phase 1	[12]
TJ4309	DMM3U2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
CPI-006	DMJSFTX	Advanced cancer	2A00-2F9Z	Phase 1	[14]
LY3475070	DMZLIWX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
NZV930	DMWN2FP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
PMID28870136-Compound-57	DME3HLC	N. A.	N. A.	Patented	[17]
PMID28870136-Compound-46	DM4FD7C	N. A.	N. A.	Patented	[17]
PMID28870136-Compound-53	DMLEWY6	N. A.	N. A.	Patented	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Not Available	[2]
Transforming growth factor beta (TGFB)	TTO3HT7	NOUNIPROTAC	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03954704) Study of GS-1423 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Agenus.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [5] A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
• [6] Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
• [7] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
• [9] TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
• [10] Clinical pipeline report, company report or official report of Roche
• [11] ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
• [12] Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
• [13] ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
• [15] CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
• [16] Clinical pipeline report, company report or official report of Surface oncology.
• [17] Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.